Danielle Antalffy
Stock Analyst at UBS
(3.44)
# 956
Out of 4,761 analysts
170
Total ratings
48.67%
Success rate
4.2%
Average return
Main Sectors:
Stocks Rated by Danielle Antalffy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDT Medtronic | Maintains: Neutral | $85 → $95 | $89.94 | +5.63% | 8 | Feb 19, 2025 | |
| BSX Boston Scientific | Maintains: Buy | $105 → $130 | $104.49 | +24.41% | 12 | Feb 7, 2025 | |
| SGHT Sight Sciences | Maintains: Buy | $5.5 → $5 | $2.53 | +97.63% | 2 | Jan 27, 2025 | |
| ABT Abbott Laboratories | Maintains: Buy | $146 → $148 | $134.92 | +9.69% | 12 | Jan 23, 2025 | |
| RXST RxSight | Initiates: Buy | $52 | $29.60 | +75.68% | 2 | Dec 6, 2024 | |
| GKOS Glaukos | Initiates: Buy | $182 | $125.88 | +44.58% | 1 | Dec 6, 2024 | |
| SYK Stryker | Maintains: Neutral | $366 → $370 | $382.78 | -3.34% | 6 | Oct 30, 2024 | |
| ATRC AtriCure | Maintains: Buy | $35 → $40 | $38.39 | +4.19% | 12 | Oct 30, 2024 | |
| EW Edwards Lifesciences | Maintains: Neutral | $90 → $75 | $73.30 | +2.32% | 12 | Sep 10, 2024 | |
| ZBH Zimmer Biomet Holdings | Maintains: Sell | $112 → $107 | $104.83 | +2.07% | 4 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6.5 → $7 | $9.37 | -25.29% | 5 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $163 → $95 | $88.78 | +7.01% | 8 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $24 → $26 | $18.90 | +37.57% | 3 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $42.71 | +75.60% | 1 | Jan 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $180 | $162.30 | +10.91% | 4 | Dec 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $405 → $322 | $177.32 | +81.59% | 5 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $2.25 | $4.30 | -47.67% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $43 | $33.82 | +27.14% | 5 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $278 | $591.79 | -53.02% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $45 | $31.00 | +45.16% | 14 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $300 → $280 | $282.80 | -0.99% | 12 | May 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $65 → $55 | $0.88 | +6,182.84% | 2 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $14 | $18.00 | -22.22% | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $100 | $78.23 | +27.83% | 2 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $12 | $13.77 | -12.85% | 3 | Mar 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $30 | $62.25 | -51.81% | 3 | Mar 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $45 | $52.00 | -13.46% | 4 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $105 → $85 | $5.73 | +1,383.42% | 10 | Feb 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $270 → $275 | $227.43 | +20.92% | 1 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $20 | $3.21 | +523.05% | 3 | Nov 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $72 → $42 | $9.91 | +323.81% | 7 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $3 | $0.96 | +212.14% | 3 | Apr 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $1.15 | +1,204.35% | 1 | Sep 1, 2020 |
Medtronic
Feb 19, 2025
Maintains: Neutral
Price Target: $85 → $95
Current: $89.94
Upside: +5.63%
Boston Scientific
Feb 7, 2025
Maintains: Buy
Price Target: $105 → $130
Current: $104.49
Upside: +24.41%
Sight Sciences
Jan 27, 2025
Maintains: Buy
Price Target: $5.5 → $5
Current: $2.53
Upside: +97.63%
Abbott Laboratories
Jan 23, 2025
Maintains: Buy
Price Target: $146 → $148
Current: $134.92
Upside: +9.69%
RxSight
Dec 6, 2024
Initiates: Buy
Price Target: $52
Current: $29.60
Upside: +75.68%
Glaukos
Dec 6, 2024
Initiates: Buy
Price Target: $182
Current: $125.88
Upside: +44.58%
Stryker
Oct 30, 2024
Maintains: Neutral
Price Target: $366 → $370
Current: $382.78
Upside: -3.34%
AtriCure
Oct 30, 2024
Maintains: Buy
Price Target: $35 → $40
Current: $38.39
Upside: +4.19%
Edwards Lifesciences
Sep 10, 2024
Maintains: Neutral
Price Target: $90 → $75
Current: $73.30
Upside: +2.32%
Zimmer Biomet Holdings
Aug 8, 2024
Maintains: Sell
Price Target: $112 → $107
Current: $104.83
Upside: +2.07%
Aug 7, 2024
Maintains: Neutral
Price Target: $6.5 → $7
Current: $9.37
Upside: -25.29%
Jul 26, 2024
Maintains: Buy
Price Target: $163 → $95
Current: $88.78
Upside: +7.01%
Feb 14, 2024
Maintains: Neutral
Price Target: $24 → $26
Current: $18.90
Upside: +37.57%
Jan 22, 2024
Initiates: Buy
Price Target: $75
Current: $42.71
Upside: +75.60%
Dec 1, 2023
Upgrades: Buy
Price Target: $180
Current: $162.30
Upside: +10.91%
Sep 6, 2023
Maintains: Buy
Price Target: $405 → $322
Current: $177.32
Upside: +81.59%
Mar 29, 2023
Initiates: Neutral
Price Target: $2.25
Current: $4.30
Upside: -47.67%
Mar 29, 2023
Initiates: Neutral
Price Target: $43
Current: $33.82
Upside: +27.14%
Mar 29, 2023
Initiates: Neutral
Price Target: $278
Current: $591.79
Upside: -53.02%
Mar 29, 2023
Initiates: Neutral
Price Target: $45
Current: $31.00
Upside: +45.16%
May 6, 2022
Maintains: Outperform
Price Target: $300 → $280
Current: $282.80
Upside: -0.99%
May 5, 2022
Maintains: Outperform
Price Target: $65 → $55
Current: $0.88
Upside: +6,182.84%
May 5, 2022
Maintains: Outperform
Price Target: $12 → $14
Current: $18.00
Upside: -22.22%
May 2, 2022
Maintains: Outperform
Price Target: $75 → $100
Current: $78.23
Upside: +27.83%
Mar 11, 2022
Maintains: Outperform
Price Target: $15 → $12
Current: $13.77
Upside: -12.85%
Mar 9, 2022
Maintains: Outperform
Price Target: $25 → $30
Current: $62.25
Upside: -51.81%
Feb 25, 2022
Maintains: Outperform
Price Target: $40 → $45
Current: $52.00
Upside: -13.46%
Feb 24, 2022
Maintains: Outperform
Price Target: $105 → $85
Current: $5.73
Upside: +1,383.42%
Feb 4, 2022
Maintains: Market Perform
Price Target: $270 → $275
Current: $227.43
Upside: +20.92%
Nov 10, 2021
Maintains: Outperform
Price Target: $26 → $20
Current: $3.21
Upside: +523.05%
Nov 5, 2021
Maintains: Market Perform
Price Target: $72 → $42
Current: $9.91
Upside: +323.81%
Apr 1, 2021
Downgrades: Market Perform
Price Target: $3
Current: $0.96
Upside: +212.14%
Sep 1, 2020
Initiates: Outperform
Price Target: $15
Current: $1.15
Upside: +1,204.35%